IL1B and acute myeloid leukemia: Despite having variable enzymatic and oligomerization activities, all the mutant proteins retained the ability to elicit IL-1β secretion from Vitamin D3 (VitD3) differentiated THP-1 monocytes (Fig 4A) and the ability to enhance primary AML cell survival (Fig 4B).